Tascenso ODT (fingolimod orally disintegrating tablets) — Medica

Relapsing forms of multiple sclerosis (clinically isolated syndrome, relapsing remitting disease, and active secondary progressive disease)

Initial criteria

Patient has a relapsing form of multiple sclerosis (examples include clinically isolated syndrome, relapsing remitting disease, and active secondary progressive disease); AND
age ≥ 10 years; AND
Medication is prescribed by or in consultation with a neurologist or a physician who specializes in the treatment of multiple sclerosis

Patient has a relapsing form of multiple sclerosis (examples include clinically isolated syndrome, relapsing remitting disease, and active secondary progressive disease); AND
age ≥ 10 years; AND
Patient meets ONE of the following (a or b):
a) Patient experienced a beneficial clinical response when assessed by at least one objective measure (examples: stabilization or reduced worsening in disease activity as evaluated by MRI, stabilization or reduced worsening on EDSS, achievement of NEDA-3 or NEDA-4, improvement on FSIQ-RMS, reduction or absence of relapses, improvement or maintenance on 6MWT or 12-Item MS Walking Scale, improvement on MSFC score, attenuation of brain volume loss); OR
b) Patient experienced stabilization, slow progression, or improvement in at least one symptom such as motor function, fatigue, vision, bowel/bladder function, spasticity, walking/gait, or pain/numbness/tingling sensation; AND
Medication is prescribed by or in consultation with a neurologist or a physician who specializes in the treatment of multiple sclerosis

1 year